USTR initiated a Section 301 investigation on June 18, 2026, concerning Germany’s persistent underpayment for innovative pharmaceutical products.

A Section 301 investigation is a review by the U.S. Trade Representative (USTR) of an alleged unreasonable, discriminatory, or burdensome practice by another country that harms U.S. commerce. In this case, the stated concern involves Germany’s alleged underpayment for innovative pharmaceutical products. An investigation is not itself a duty or import ban; after reviewing evidence and receiving comments, USTR may take no action or may recommend measures such as additional duties or other trade remedies.

The measure may affect German manufacturers, U.S. importers, distributors, healthcare suppliers, and businesses whose products or supply chains involve covered pharmaceutical goods. Its practical effect depends on the investigation’s scope and any later official action. Importers should distinguish the country named in the investigation from the product’s legal country of origin and should not assume that every pharmaceutical product, German supplier, or shipment is covered.

What to check

• Read the official USTR notice and any later determination to identify the covered conduct, products, countries, and measure status.
• Verify the product’s tariff classification under the Harmonized Tariff Schedule of the United States (HTSUS), including the relevant pharmaceutical heading or subheading.
• Confirm customs country of origin using applicable origin rules; the supplier’s location, shipping route, and place of purchase may not determine origin.
• Check whether any additional duty, exclusion, quota, licensing condition, or effective-date rule has actually been issued before entry.
• Ask a licensed customs broker or trade counsel to review ambiguous product scope, pharmaceutical formulations, processing history, and documentation requirements.